Evidence map›Paper›PMID 33442689›Full record

ArticlebioRxiv : the preprint server for biology2021

COVID-19 virtual patient cohort reveals immune mechanisms driving disease outcomes.

Adrianne L Jenner, Rosemary A Aogo, Sofia Alfonso, Vivienne Crowe, Amanda P Smith, Penelope A Morel, Courtney L Davis, Amber M Smith, Morgan Craig

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 22 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Adrianne L JennerCHU Sainte-Justine Research Centre, Montréal, Québec, Canada.
Rosemary A AogoDepartment of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Sofia AlfonsoDepartment of Physiology, McGill University, Montréal, Québec, Canada.
Vivienne CroweDepartment of Mathematics and Statistics, Concordia University, Montréal, Québec, Canada.
Amanda P SmithDepartment of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Penelope A MorelDepartment of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Courtney L DavisNatural Science Division, Pepperdine University, Malibu, California, USA.
Amber M SmithDepartment of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Morgan CraigCHU Sainte-Justine Research Centre, Montréal, Québec, Canada.
University of Tennessee Health Science Center · USCentre Hospitalier Universitaire Sainte-Justine · CAConcordia University · CAMcGill University · CAPepperdine University · USUniversity of Pittsburgh · US

Funding

Predictive Modeling of Influenza-Pneumococcal CoinfectionR01AI139088 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI SMITH, AMBER M · 2018 to 2022
$2.1M
NIAID NIH HHS R01 AI139088
6 · The paper itself

Abstract

To understand the diversity of immune responses to SARS-CoV-2 and distinguish features that predispose individuals to severe COVID-19, we developed a mechanistic, within-host mathematical model and virtual patient cohort. Our results indicate that virtual patients with low production rates of infected cell derived IFN subsequently experienced highly inflammatory disease phenotypes, compared to those with early and robust IFN responses. In these AUTHOR SUMMARY: Understanding of how the immune system responds to SARS-CoV-2 infections is critical for improving diagnostic and treatment approaches. Identifying which immune mechanisms lead to divergent outcomes can be clinically difficult, and experimental models and longitudinal data are only beginning to emerge. In response, we developed a mechanistic, mathematical and computational model of the immunopathology of COVID-19 calibrated to and validated against a broad set of experimental and clinical immunological data. To study the drivers of severe COVID-19, we used our model to expand a cohort of virtual patients, each with realistic disease dynamics. Our results identify key processes that regulate the immune response to SARS-CoV-2 infection in virtual patients and suggest viable therapeutic targets, underlining the importance of a rational approach to studying novel pathogens using intra-host models.

Identifiers

PMID33442689
PMCPMC7805446
OpenAlexW3118261491

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.